LYMPHOMA: Several studies from ASH reported significant activity and impressive response rates for different bispecific antibodies (mainly CD3 and CD19 or CD20).

Web

Dec. 16, 2019

SCIENTIFIC

LYMPHOMA Several studies from ASH reported significant activity and impressive response rates for different bispecific antibodies (mainly CD3 and CD19 or CD20).

Could this approach eclipse expensive CAR-T cell therapies?

61st ASH Annual Meeting & Exposition The premier event in malignant and non-malignant hematology Orlando, FL  (December 7-10, 2019)

 

Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma :

Paper Number: 1585  Presenter: Genevive Hernandez

 

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Paper Number: 2871 Presenter: Martin Hutchings

 

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Paper Number: 1874 Presenter: Ben Buelow

 

MORE ABSTRACTS HERE